Sign In
Buy SRPT
$16.24
-0.0100 (-0.0615%)
At Close: Jun 03, 2026
Public Sector Pension Investment Board Purchases Shares of 381,172 Sarepta Therapeutics, Inc. $SRPT
04:04am, Wednesday, 18'th Feb 2026
Public Sector Pension Investment Board acquired a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) in the undefined quarter, according to the company in its most recent Form 13F filing
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
08:30am, Wednesday, 11'th Feb 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2025 financial results
Head to Head Survey: Edgewise Therapeutics (NASDAQ:EWTX) and Sarepta Therapeutics (NASDAQ:SRPT)
04:44am, Tuesday, 10'th Feb 2026
Edgewise Therapeutics (NASDAQ: EWTX - Get Free Report) and Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two co
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of “Hold” by Brokerages
02:37am, Thursday, 05'th Feb 2026
Shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT - Get Free Report) have earned an average rating of "Hold" from the twenty-eight brokerages that are presently covering the stock, Marketbeat.com rep
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease
08:30am, Wednesday, 04'th Feb 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that Medsafe, the New Zealand Medicines and Med
Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags
04:38am, Sunday, 01'st Feb 2026
Sarepta Therapeutics (NASDAQ: SRPT) reported three-year top-line results from its EMBARK Phase 3 pivotal trial evaluating ELEVIDYS, highlighting what executives described as the first large, well-cont
SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
11:50am, Tuesday, 27'th Jan 2026
SRPT jumps nearly 8% after Elevidys shows sustained motor gains and slower progression three years post-dose in the phase III EMBARK DMD study.
Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript
Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Monday, 26'th Jan 2026
Sarepta Therapeutics (SRPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sarepta Therapeutics shares rise on positive Duchenne gene therapy data
10:40am, Monday, 26'th Jan 2026
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares moved higher in early trade on Monday as it reported positive topline three-year results from its Phase 3 EMBARK study evaluating its gene therapy ELEVIDY
Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys
08:53am, Monday, 26'th Jan 2026
Sarepta reports positive, statistically significant results in a study evaluating the efficacy of its blockbuster gene therapy.
Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows
08:10am, Monday, 26'th Jan 2026
Sarepta Therapeutics' gene therapy for a progressive muscle‑wasting disorder showed sustained benefit in patients' ability to control and coordinate movement, according to three‑year data from a l
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced positive topline three-year functional results
Sarepta Therapeutics shares rise on positive Duchenne gene therapy data
05:38am, Monday, 26'th Jan 2026
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares moved higher in early trade on Monday as it reported positive topline three-year results from its Phase 3...
Stock Market Today: Dow Jones, S&P 500 Futures Slip As Investors Brace For Mega-Cap Earnings—Brand Engagement, Nucor In Focus
05:36am, Monday, 26'th Jan 2026
U.S. stock futures dropped on Monday following Friday's mixed close. Futures of major benchmark indices were lower.
